On June 7, Chiatai Tianqing Pharmaceutical Group and China Resources Pharmaceutical Commercial signed a strategic cooperation agreement in Tianjin. Based on the principle of resource sharing, complementary advantages and common development, the two parties will carry out in-depth cooperation in the fields of pharmaceutical research and development, production, sales and circulation, and jointly help the sustainable development of China’s pharmaceutical industry. Chiatai Tianqing’s commercial director Qi Tianze and CR Pharmaceuticals Commercial Deputy General Manager Dong Hao signed the agreement on behalf of the two parties. As one of the leading pharmaceutical companies in China, Chiatai Tianqing has always been committed to researching and developing innovative drugs, improving drug quality and meeting patients’ needs. With strong R&D strength and market competitiveness, the company has won wide recognition and trust. As an important pillar industry of China Resources Group, China Resources Pharmaceutical Commercial has a comprehensive pharmaceutical distribution network and market channels, ...
Affecting more than 7 million people in the UK, cardiovascular diseases are conditions that affect the heart or circulation The British Heart Foundation (BHF) has awarded a total of £35m in funding to nine universities across the UK to help strengthen world-leading cardiovascular disease research. Provided through BHF’s Research Excellence Awards scheme, the funding will support research environments that encourage collaboration, inclusion and innovation to accelerate lifesaving breakthroughs. Affecting around 7.6 million people in the UK, cardiovascular disease is a term for conditions that affect the heart or circulation, including high blood pressure, stroke, heart disease and vascular dementia. The nine universities to receive part of the funding include Imperial College London (ICL), King’s College London (KCL), the University of Cambridge, Edinburgh, Leeds, Leicester, Manchester, Oxford and University College London. For the next five years, the funding will enable cutting-edge research to address some of the biggest cardiovascular disease challenges, ...
“The introduction of the ‘old for new’ policy is good news for the entire medical market, especially for companies like us that have been rooted in China for many years.” Pu Zhengrong, vice president of Siemens Healthineers Greater China and head of clinical treatment systems, expressed the above views in an interview with China News Service recently. At the 89th China International Medical Equipment (Spring) Fair (CMEF) which just ended in Shanghai, the “old for new” policy for medical equipment was undoubtedly a hot topic. Faced with the trillion-level market released by this policy, a number of multinational companies showed great interest. Chen Jinlei, vice president of GE Healthcare China and general manager of medical imaging business, said that after the “old for new” policy was released, the medical industry, from users to manufacturers, paid close attention to it. “We have developed eight targeted plans for ‘old for new’.” On ...
The proposals will help MedTech developers access NHS funding to fast-track products NHS England and the National Institute for Health and Care Excellence (NICE) have announced a new plan to adopt innovative medical technologies to provide faster access to NICE-recommended products and improve patient outcomes. The proposals set out a route for MedTech developers to access NHS funding to fast-track clinically and cost-effective products to be used by NHS England. Developed by NHS England and NICE with input from the Department of Health and Social Care, as well as other partners including the Office for Life Science and the Medicines and Healthcare products Regulatory Agency, the new plans will also support MedTech innovators and suppliers with automatic funding to support routine commissioning for technologies that meet the required criteria. NHS England’s interim medical director for transformation, Dr Vin Diwaker, said: “Medical technology plays a vital role in the nation’s health ...
Entod Pharmaceuticals has launched Vitamin D3 enriched lubricating eye drops. These novel formulations aim to benefit ocular health, providing targeted relief for individuals suffering from dry eyes. Vitamin D3 has now been incorporated into some of Entod’s selected lubricant eye drop brands that are currently prescribed by eye doctors for dry eyes. Dry eye syndrome is a prevalent condition characterised by discomfort, irritation, and even vision impairment. The main causes of dry eyes are environmental factors, Vitamin deficiencies, Poor blinking habits, Contact lenses, Digital devices, Smoking, Refractive surgeries and more. Commenting on the launch, Nikkhil K Masurkar, CEO, Entod said, “ Adding Vitamin D3 to routine dry eye treatment improves ocular surface hemostasis parameters, results in better tear stability, improves tear osmolarity, and helps modulate corneal wound healing. Vitamin D3 enriched lubricating eye drops would only be available through health care professional prescriptions.” Emphasising the significance of Vitamin D on ...
Mike Hollan Cencora’s associate director of value and access strategy for its commercialization strategy & access solutions division discusses the current state of pre-approval information exchanges. Alvana Maliqi, Associate director of value and access strategy Alvana Maliqi served as lead author on Cencora’s latest research initiatives focused on pre-approval information exchange (PIE). She spoke with Pharmaceutical Executive about the research and how the industry can utilize this information more efficiently. Pharma Executive: What does the passage of the PIE legislation allow biopharma companies to do? Alvana Maliqi: The Consolidated Appropriations Act, 20231 (or pre-approval information exchange [PIE] legislation”) was signed into law in 2022, providing a safe harbor for pharmaceutical companies to proactively engage in PIE with payers about new products and/or new indications. Previously, this pathway was initially supported by the 2018 FDA Final Guidance for pre-approval communications. Since 2018, biopharma manufacturers are permitted to share unbiased, factual, accurate, ...
Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the safety and regulatory rigor Parexel and Palantir Technologies has announced a multi-year strategic partnership to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharma customers. Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform, focused on driving clinical trial efficiency while maintaining the safety and regulatory rigor. Parexel is the first CRO working with Palantir in this capacity, building on the companies’ existing collaboration over the past year. Jonathan Shough, Chief Information Officer for Parexel said, “We’re thrilled to expand our collaboration with Palantir — a leader in artificial intelligence technology — as we build on our application of AI ...
Infections from soil-transmitted helminths (STHs), commonly known as intestinal parasitic worms, are among the most widespread neglected tropical diseases and impose a significant health burden in low- and middle-income countries, particularly among school-aged children. These infections often lead to chronic health issues that can cause disability, social stigma, and for their substantial economic impacts on communities. STHs are notorious role in nutrient loss, which can contribute to neurocognitive impairments, stunted growth and development, and persistent fatigue in affected children. Additionally, these parasites are a major cause of morbidity and complications during pregnancy. The standard diagnostic method for STHs involves manual microscopy, which requires up to 10 minutes per slide and is hindered by a lack of skilled professionals and access to necessary equipment and lab infrastructure in highly affected regions. There is a pressing need for improved diagnostic techniques, particularly for detecting infections of mild intensity, to effectively manage and ...
Bio-Rad Laboratories and Oncocyte Corporation have partnered to develop and commercialise solid tissue transplant monitoring products for researchers and laboratories to “advance science and save lives”. The collaboration will utilise Bio-Rad’s Droplet Digital Polymerase Chain Reaction (ddPCR) technology. Solid organ transplantation is a medical procedure to treat end-stage organ failure of the kidneys, liver, pancreas, heart and lung. Currently the most commonly transplanted organ worldwide, kidney transplantation was performed more than 42,800 times in 2022, according to the United Network for Organ Sharing. Under the terms of the agreement, Bio-Rad has agreed to participate in a private placement of Oncocyte’s equity and has secured exclusive commercial rights in certain markets to commercialise the precision diagnostics company’s assay for transplant monitoring research using the QX600 ddPCR system. When organs are transplanted, cell-free DNA, otherwise known as donor-derived cell-free DNA (dd-cfDNA), a sensitive biomarker for organ health that requires a simple blood ...
Set to open in 2032, the RUEDI facility is funded by the UKRI’s recent infrastructure fund worth £388m The University of Liverpool has announced that it will be leading a national research facility worth £125m to drive scientific discovery and advance technologies as part of the UK Research and Innovation’s (UKRI) infrastructure fund worth £388m. The Relativistic Ultrafast Electron Diffraction and Imaging (RUEDI) facility will benefit areas of research including quantum technologies and personalised medicine. The UKRI recently announced five new infrastructure projects with new funding to equip the UK’s research and innovation bases, with an additional £85m for the UKRI’s Digital Research Infrastructure Programme. In collaboration with the University of Liverpool’s Science and Technology Facilities Council and the Rosalind Franklin Institute, the new facility will allow researchers to explore changes in living cells as they happen to develop more personalised treatments for patients in a more renewable and sustainable ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.